explore -WSS

explore

author：knowledge 2025-09-27 07:51:12 - browse：6

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： New brain studies show LSD's effects on the brain in full color

focus

WSS

EU regulator recommends expanding Mounjaro approval to obesity

Prior authorization will have to move faster under new Biden rule

Custom gene therapy hints at new path for rare disease treatments

Readout Newsletter: Merck, J&J, and long Covid

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Biotech venture capitalists face new demands from investors

explore

explore

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

George Santos makes 1st court appearance after pleading not guilty to 13 counts

NIH director takes cautious approach to Biden drug pricing priority

Wildfire smoke exposes gaps in outdoor worker protections

Eli Lilly, Pfizer, and others want in on the online prescription market

New air purifier tech could be key to improving indoor air quality

How digital therapeutics firms are pivoting after Pear's bankruptcy

Jerome Adams on the need for new antivirals for Covid

Biden tests positive for Covid

focus

At Orexo, a ‘turning point’ for everything but digital health

In early work, researchers turn to CRISPR to treat Alzheimer's

Francis Collins on trust in science and how Covid communications failed

FDA approves RSV monoclonal antibody for infants, toddlers

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

The surgeon had a dilemma only a Nazi medical text could resolve

explore

focus

knowledge

focus